A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions
This study has been completed.
Sponsor:
Actavis Inc.
Information provided by:
Actavis Inc.
ClinicalTrials.gov Identifier:
NCT00865111
First received: March 17, 2009
Last updated: August 13, 2010
Last verified: August 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare the rate and extent of absorption of Abrika Bupropion 150 mg sustained release tablet to that of Wellbutrin SR sustained release tablet after a single, one-tablet dose in fasted subjects.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Drug: Bupropion 150 mg Extended-Released Tablet, single dose Drug: Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Bio-equivalence Study Intervention Model: Crossover Assignment Masking: Open Label |
| Official Title: | A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion Sustained Release Tablets in Fasted, Normal, Healthy Men. |
Resource links provided by NLM:
Further study details as provided by Actavis Inc.:
Primary Outcome Measures:
- Rate and Extend of Absorption [ Time Frame: 120 hours ] [ Designated as safety issue: No ]
| Enrollment: | 26 |
| Study Start Date: | March 2006 |
| Study Completion Date: | April 2006 |
| Primary Completion Date: | April 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A
Bupropion 150 mg Extended-Released Tablet, single dose
|
Drug: Bupropion 150 mg Extended-Released Tablet, single dose
A: Experimental Subjects received Abrika formulated products under fasting conditions
Other Name: Bupropion
|
|
Active Comparator: B
Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
|
Drug: Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
Other Name: Bupropion
|
Detailed Description:
Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design.
Official Title: A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion Sustained Release Tablets in Fasted, Normal, Healthy Men.
Further study details as provided by Actavis Elizabeth LLC:
Primary Outcome Measures:
Rate and Extend of Absorption
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Is the individual a healthy, normal adult man who volunteers to participate?
- Is he 18-45 years of age, inclusive?
- Is his BMI between 19 and 30, inclusive?
- Is he considered reliable and capable of understanding his responsibility and role in the study?
- Has he provided written informed consent? A no answer to any of the above questions indicates that the individual is ineligible for enrollment
Exclusion Criteria:
- Does the individual have a history of allergy or hypersensitivity to bupropion?
- Does he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his safety?
- Does he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, renal or other diseases, conditions or surgeries that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
- Does he have serious psychological illness?
- Does he have significant history (within the past year) or clinical evidence of alcohol or drug abuse?
- Does he have a positive urine drug screen or saliva alcohol screen, or a positive HIV-l, or hepatitis B or C screen?
- Has he consumed grapefruit or grapefruit juice during the 7-day period preceding study initiation?
- Is he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken in each study period?
- Has he used any prescription drug during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation?
- Is he unable to refrain from the use of all concomitant medications during the study?
- Has he donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation?
- Has he donated plasma during the two week period preceding study initiation?
- Has he received an investigational drug during the 30 day period preceding study initiation?
- Is he a heavy smoker (usually smoking more than 25 cigarettes per day? A yes answer to any of the above questions indicates that the individual is ineligible for enrollment
Contacts and Locations More Information
Additional Information:
No publications provided
| Responsible Party: | Meena Venugopal, Director, Clinical R&D, Actavis Inc |
| ClinicalTrials.gov Identifier: | NCT00865111 History of Changes |
| Other Study ID Numbers: | 06-0646-001 |
| Study First Received: | March 17, 2009 |
| Last Updated: | August 13, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Actavis Inc.:
|
Bioequivalence Bupropion Healthy subjects |
Additional relevant MeSH terms:
|
Bupropion Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Central Nervous System Agents Therapeutic Uses Pharmacologic Actions |
Dopamine Uptake Inhibitors Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Neurotransmitter Uptake Inhibitors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 16, 2013